Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients

Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the o...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sun, Xiaojun [verfasserIn] Song, Zhengbo [verfasserIn] Jiang, Hongyang [verfasserIn] Ma, Yanqing [verfasserIn] Chen, Ming [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification

Übergeordnetes Werk:	Enthalten in: Clinical imaging - Amsterdam [u.a.] : Elsevier Science, 1989, 86, Seite 31-37
Übergeordnetes Werk:	volume:86 ; pages:31-37

DOI / URN:	10.1016/j.clinimag.2022.03.012

Katalog-ID:	ELV007759703

Internformat


LEADER	01000caa a22002652 4500
001	ELV007759703
003	DE-627
005	20230524165120.0
007	cr uuu---uuuuu
008	230507s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.clinimag.2022.03.012 \|2 doi
035			\|a (DE-627)ELV007759703
035			\|a (ELSEVIER)S0899-7071(22)00075-4
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 610 \|q DE-600
084			\|a 44.64 \|2 bkl
100	1		\|a Sun, Xiaojun \|e verfasserin \|4 aut
245	1	0	\|a Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
264		1	\|c 2022
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.
650		4	\|a Immune checkpoint inhibitor (ICI)
650		4	\|a Immune-related adverse events
650		4	\|a Immune checkpoint inhibitor–related pneumonia (ICIP)
650		4	\|a Lung cancer
650		4	\|a Image classification
700	1		\|a Song, Zhengbo \|e verfasserin \|4 aut
700	1		\|a Jiang, Hongyang \|e verfasserin \|4 aut
700	1		\|a Ma, Yanqing \|e verfasserin \|4 aut
700	1		\|a Chen, Ming \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Clinical imaging \|d Amsterdam [u.a.] : Elsevier Science, 1989 \|g 86, Seite 31-37 \|h Online-Ressource \|w (DE-627)320437914 \|w (DE-600)2004578-5 \|w (DE-576)261857592 \|x 1873-4499 \|7 nnns
773	1	8	\|g volume:86 \|g pages:31-37
912			\|a GBV_USEFLAG_U
912			\|a SYSFLAG_U
912			\|a GBV_ELV
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_224
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
936	b	k	\|a 44.64 \|j Radiologie
951			\|a AR
952			\|d 86 \|h 31-37

Indexfelder

author_variant	x s xs z s zs h j hj y m ym m c mc
matchkey_str	article:18734499:2022----::mgcasfctooimncekonihbtreaepemn
hierarchy_sort_str	2022
bklnumber	44.64
publishDate	2022
allfields	10.1016/j.clinimag.2022.03.012 doi (DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl Sun, Xiaojun verfasserin aut Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice. Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification Song, Zhengbo verfasserin aut Jiang, Hongyang verfasserin aut Ma, Yanqing verfasserin aut Chen, Ming verfasserin aut Enthalten in Clinical imaging Amsterdam [u.a.] : Elsevier Science, 1989 86, Seite 31-37 Online-Ressource (DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592 1873-4499 nnns volume:86 pages:31-37 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 44.64 Radiologie AR 86 31-37
spelling	10.1016/j.clinimag.2022.03.012 doi (DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl Sun, Xiaojun verfasserin aut Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice. Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification Song, Zhengbo verfasserin aut Jiang, Hongyang verfasserin aut Ma, Yanqing verfasserin aut Chen, Ming verfasserin aut Enthalten in Clinical imaging Amsterdam [u.a.] : Elsevier Science, 1989 86, Seite 31-37 Online-Ressource (DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592 1873-4499 nnns volume:86 pages:31-37 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 44.64 Radiologie AR 86 31-37
allfields_unstemmed	10.1016/j.clinimag.2022.03.012 doi (DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl Sun, Xiaojun verfasserin aut Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice. Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification Song, Zhengbo verfasserin aut Jiang, Hongyang verfasserin aut Ma, Yanqing verfasserin aut Chen, Ming verfasserin aut Enthalten in Clinical imaging Amsterdam [u.a.] : Elsevier Science, 1989 86, Seite 31-37 Online-Ressource (DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592 1873-4499 nnns volume:86 pages:31-37 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 44.64 Radiologie AR 86 31-37
allfieldsGer	10.1016/j.clinimag.2022.03.012 doi (DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl Sun, Xiaojun verfasserin aut Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice. Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification Song, Zhengbo verfasserin aut Jiang, Hongyang verfasserin aut Ma, Yanqing verfasserin aut Chen, Ming verfasserin aut Enthalten in Clinical imaging Amsterdam [u.a.] : Elsevier Science, 1989 86, Seite 31-37 Online-Ressource (DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592 1873-4499 nnns volume:86 pages:31-37 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 44.64 Radiologie AR 86 31-37
allfieldsSound	10.1016/j.clinimag.2022.03.012 doi (DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl Sun, Xiaojun verfasserin aut Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice. Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification Song, Zhengbo verfasserin aut Jiang, Hongyang verfasserin aut Ma, Yanqing verfasserin aut Chen, Ming verfasserin aut Enthalten in Clinical imaging Amsterdam [u.a.] : Elsevier Science, 1989 86, Seite 31-37 Online-Ressource (DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592 1873-4499 nnns volume:86 pages:31-37 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 44.64 Radiologie AR 86 31-37
language	English
source	Enthalten in Clinical imaging 86, Seite 31-37 volume:86 pages:31-37
sourceStr	Enthalten in Clinical imaging 86, Seite 31-37 volume:86 pages:31-37
format_phy_str_mv	Article
bklname	Radiologie
institution	findex.gbv.de
topic_facet	Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification
dewey-raw	610
isfreeaccess_bool	false
container_title	Clinical imaging
authorswithroles_txt_mv	Sun, Xiaojun @@aut@@ Song, Zhengbo @@aut@@ Jiang, Hongyang @@aut@@ Ma, Yanqing @@aut@@ Chen, Ming @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	320437914
dewey-sort	3610
id	ELV007759703
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV007759703</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524165120.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230507s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clinimag.2022.03.012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV007759703</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0899-7071(22)00075-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Xiaojun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitor (ICI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune-related adverse events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitor–related pneumonia (ICIP)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Image classification</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Zhengbo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Hongyang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Yanqing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ming</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical imaging</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1989</subfield><subfield code="g">86, Seite 31-37</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)320437914</subfield><subfield code="w">(DE-600)2004578-5</subfield><subfield code="w">(DE-576)261857592</subfield><subfield code="x">1873-4499</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:86</subfield><subfield code="g">pages:31-37</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="j">Radiologie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">86</subfield><subfield code="h">31-37</subfield></datafield></record></collection>
author	Sun, Xiaojun
spellingShingle	Sun, Xiaojun ddc 610 bkl 44.64 misc Immune checkpoint inhibitor (ICI) misc Immune-related adverse events misc Immune checkpoint inhibitor–related pneumonia (ICIP) misc Lung cancer misc Image classification Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
authorStr	Sun, Xiaojun
ppnlink_with_tag_str_mv	@@773@@(DE-627)320437914
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
issn	1873-4499
topic_title	610 DE-600 44.64 bkl Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients Immune checkpoint inhibitor (ICI) Immune-related adverse events Immune checkpoint inhibitor–related pneumonia (ICIP) Lung cancer Image classification
topic	ddc 610 bkl 44.64 misc Immune checkpoint inhibitor (ICI) misc Immune-related adverse events misc Immune checkpoint inhibitor–related pneumonia (ICIP) misc Lung cancer misc Image classification
topic_unstemmed	ddc 610 bkl 44.64 misc Immune checkpoint inhibitor (ICI) misc Immune-related adverse events misc Immune checkpoint inhibitor–related pneumonia (ICIP) misc Lung cancer misc Image classification
topic_browse	ddc 610 bkl 44.64 misc Immune checkpoint inhibitor (ICI) misc Immune-related adverse events misc Immune checkpoint inhibitor–related pneumonia (ICIP) misc Lung cancer misc Image classification
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Clinical imaging
hierarchy_parent_id	320437914
dewey-tens	610 - Medicine & health
hierarchy_top_title	Clinical imaging
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320437914 (DE-600)2004578-5 (DE-576)261857592
title	Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
ctrlnum	(DE-627)ELV007759703 (ELSEVIER)S0899-7071(22)00075-4
title_full	Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
author_sort	Sun, Xiaojun
journal	Clinical imaging
journalStr	Clinical imaging
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2022
contenttype_str_mv	zzz
container_start_page	31
author_browse	Sun, Xiaojun Song, Zhengbo Jiang, Hongyang Ma, Yanqing Chen, Ming
container_volume	86
class	610 DE-600 44.64 bkl
format_se	Elektronische Aufsätze
author-letter	Sun, Xiaojun
doi_str_mv	10.1016/j.clinimag.2022.03.012
dewey-full	610
author2-role	verfasserin
title_sort	image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
title_auth	Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
abstract	Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.
abstractGer	Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.
abstract_unstemmed	Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.
collection_details	GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393
title_short	Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients
remote_bool	true
author2	Song, Zhengbo Jiang, Hongyang Ma, Yanqing Chen, Ming
author2Str	Song, Zhengbo Jiang, Hongyang Ma, Yanqing Chen, Ming
ppnlink	320437914
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.clinimag.2022.03.012
up_date	2024-07-06T17:21:52.322Z
_version_	1803851149946650624
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV007759703</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524165120.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230507s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clinimag.2022.03.012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV007759703</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0899-7071(22)00075-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Xiaojun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Immune checkpoint inhibitor–related pneumonia (ICIP) is an independent risk factor for immunotherapy-related death.Purpose: To evaluate the ICIP, dynamic observation of computed tomography (CT) images of lung cancer patients with ICIP was conducted to study the relationship between the occurrence of ICIP and clinical information.Material and methods: CT images and clinical information of lung cancer patients (n = 76) from two hospitals who received immune checkpoint inhibitor (ICI) treatment were collected. A total of 49 cases were enrolled after screening according to the inclusion and exclusion criteria. We performed statistical analysis on the imaging features and clinical information.Results: Analysis of imaging characteristics revealed two types of ICIP: the limited-onset type and diffuse-onset type. The median onset time of limited-onset ICIP was significantly earlier than that of diffuse-onset ICIP (1.5 months vs. 2.8 months; p = 0.045). Statistical analysis based on differences within the group showed that the clinical ICIP grade and immunotherapy response rate of limited-onset cases were statistically significant (p = 0.003) and the imaging/clinical ICIP grade and the outcome of ICIP were statistically significant (p = 0.031/0.007). The immunotherapy strategy of diffuse-onset cases and the response rate of immunotherapy were statistically significant (p = 0.016).Conclusions: This study suggests that pre-existing lung lesions can be one of the possible predisposing factors for ICIP and describes the development of ICIP through continuous imaging. Our findings indicate pre-existing lung lesions as a referential monitoring target for the onset and progression of ICIP for clinical practice.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitor (ICI)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune-related adverse events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitor–related pneumonia (ICIP)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Image classification</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Zhengbo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Hongyang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Yanqing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ming</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical imaging</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1989</subfield><subfield code="g">86, Seite 31-37</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)320437914</subfield><subfield code="w">(DE-600)2004578-5</subfield><subfield code="w">(DE-576)261857592</subfield><subfield code="x">1873-4499</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:86</subfield><subfield code="g">pages:31-37</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="j">Radiologie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">86</subfield><subfield code="h">31-37</subfield></datafield></record></collection>
score	7.399272

Nicht das Richtige dabei?

Schreiben Sie uns!

Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?